Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  All shares of the Class A common stock, $0.0001 par value per share (the "Common Stock") of Ginkgo Bioworks Holdings, Inc. (the "Issuer") held by Cascade Investment, L.L.C. ("Cascade") may be deemed to be beneficially owned by William H. Gates III as the sole member of Cascade. The number of shares beneficially owned includes 299,052 earn-out shares that will vest in substantially equal installments if the Issuer's Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds certain thresholds as set forth in the Merger Agreement, dated as of May 11, 2021, by and among Soaring Eagle Acquisition Corp., SEAC Merger Sub Inc. and Ginkgo Bioworks, Inc., as amended (the "Merger Agreement"). Item 11 is based on 48,523,595 shares of Common Stock outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  All shares of the Common Stock of the Issuer held by Cascade may be deemed to be beneficially owned by William H. Gates III as the sole member of Cascade. The number of shares beneficially owned includes 299,052 earn-out shares that will vest in substantially equal installments if the Issuer's Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds certain thresholds as set forth in the Merger Agreement. Item 11 is based on 48,523,595 shares of Common Stock outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 6, 2025.


SCHEDULE 13G



 
Cascade Investment, L.L.C.
 
Signature:/s/ Alan Heuberger
Name/Title:Alan Heuberger, Attorney-in-fact for Michael Larson, Business Manager
Date:11/14/2025
 
William H. Gates III
 
Signature:/s/ Alan Heuberger
Name/Title:Alan Heuberger, Attorney-in-fact
Date:11/14/2025

Comments accompanying signature:  This Amendment is being filed jointly by the Reporting Persons pursuant to the Joint Filing Agreement dated September 24, 2021, and included with the signature page to the Reporting Persons' Schedule 13G with respect to the Issuer filed on September 24, 2021, SEC File No. 005-92710, and incorporated by reference herein. Duly authorized under Special Limited Power of Attorney appointing Alan Heuberger attorney-in-fact, dated October 11, 2013, by and on behalf of Michael Larson, filed as Exhibit 99.1 to Amendment No. 9 to Cascade's Schedule 13D with respect to Western Asset/Claymore Inflation-Linked Opportunities & Income Fund on December 11, 2013, SEC File No. 005-81261, and incorporated by reference herein. Duly authorized under Special Limited Power of Attorney appointing Alan Heuberger attorney-in-fact, dated August 12, 2008, by and on behalf of William H. Gates III, filed as Exhibit 99.2 to Amendment No. 1 to Cascade's Schedule 13D with respect to Otter Tail Corporation on April 15, 2009, SEC File No. 005-06638, and incorporated by reference herein.